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ABSTRACT
Objective: The research is designed at formulating and evaluating pH-sensitive rifaximin colon-targeted tablets for targeted action in proximal 
colon.
Method: The colon-targeted tablets are done by granulation of three levels of polymers such as Eudragit L30D, Carbopol 974P, and ethyl cellulose. 
The evaluation parameters such as swelling studies, drug dissolution, in vitro drug release studies, stability, and the Fourier transform infrared studies 
carried out for optimized formulations.
Results: Physicochemical parameters of all the 27 formulations (RF1-RF27) evaluated and RF21 is chosen for further investigation based on weight 
variation, hardness, drug content, and swelling index. The in vitro drug release studies indicate that the optimized formulation RF21 released 98.75% 
drug within 24 h. The stability studies indicate that the formulation is stable.
Conclusion: An effective and stable pH-dependent rifaximin colon-targeted tablet formulated for the targeted treatment of bowel syndrome.
Keywords: Rifaximin, Colon drug delivery system, Swelling index, Irritable bowel syndrome.
INTRODUCTION
The drug delivery systems are aimed at supplying the drug to an object 
site in a body. Drug delivery systems alter drug dissolution profile 
for increasing the product efficacy [1]. Colon drug delivery system 
is targeted to deliver the drug to of gastrointestinal (GI) tract [2]. 
Conventional oral administrated drugs lack the special property of 
drug targeting to GI sites. The colon-targeted drug delivery systems 
are applied for the treatment of bowel diseases and colonic cancer. The 
colon-specific drug delivery systems (CDDSs) protect the drug till it 
reaches the colon, ensuring that the drug is not released in stomach 
or small intestine. They possess long retention time of 4–5 days, thus 
facilitating maximum adsorption of drug, hence, making it ideal for 
targeted delivery [3]. CDDS applied to reduce the dosing frequency of 
drug, to deliver the drug to regions that have less hostile metabolic, 
to increase the pharmacological activity, and to prevent drug from 
degradation [4].
CDDS depends on pH and spreadability of the drug, the delivery system, 
GI transits time and the interaction level between the same [5]. The 
release of drug in GI tract also depends on ability of enzymes to break 
bonds between drug and carrier molecules. CDDSs with maximum drug 
release are considered ideal for colon release.
Among various approaches, the less suitable method is pH-dependent 
system due to variations in pH of GI tract. In spite of these intra- and 
inter-subject variations, these were considered better when combined 
with time-dependent systems [6].
Rifaximin is used in the treatment of hepatic encephalopathy, 
diarrhea, and bowel syndromes. Rifaximin acts by inhibiting RNA 
synthesis in susceptible bacteria by binding to the beta-subunit 
of bacterial deoxyribonucleic acid-dependent ribonucleic acid 
polymerase enzyme [7]. This blocks translocation steps that form 




Rifaximin was procured from Hetero Drugs Ltd., Hyderabad, India. 
Eudragit RL 100, HPMC K4M, and ethyl cellulose were purchased from 
Aurobindo Labs, India. All other chemicals and solvents were used 
without further purification.
Instruments
The formulations carried out using tablet compression machine 
(Cadmach, Ahmedabad) and dissolution apparatus (Electrolab 
[TDT- 08L], Mumbai). Chemical analysis was performed using Fourier 
transform infrared (FTIR) spectrophotometer (Shimadzu 8400S, Japan) 
and ultraviolet (UV)-visible spectrometer (Shimadzu, Japan).
Preparation of colon-targeted tablets of rifaximin
Twenty-seven formulations (RF1-RF27) were prepared using polymers 
such as Eudragit L30D, Carbopol 974P, and ethyl cellulose. The 33 response 
surface method adopted for design of experiment. The formulations with 
varied polymer concentration prepared. All the prepared formulations were 
constituted with magnesium stearate. The mixture was passed through sieve 
no 85. The polyvinylpyrrolidone K 30 and 5% in isopropyl alcohol were 
chosen as binder solvent for granulation. The wet crude passed through 
sieve no 12#. Contents dried for 2 h at 45°C. The obtained material was 
compressed with 10 mm flat punch after screening through sieve no.18#.
Evaluation of rifaximin colon-targeted tablets
Weight variation test
The average weight of 20 tablets determined randomly. Each tablet 
weighed individual and checked for deviation from average weight. The 
percentage deviation tabulated [8].
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Thicknesses
The thickness measured in millimeters using a screw gauge for 10 
tablets. The average thickness calculated. The deviation of each of 10 
tablets from average thickness noted as the standard deviation.
Hardness
The hardness is measured as tensile strength in kg/cm2 by tablet 
hardness testing machine. Randomly selected three tablets and tested 
for hardness. The average of all three values calculated [9].
Friability
The Roche friabilator (Electrolab, India) is used for determining 
friability of tablets. Twenty tablets placed in machine and run for 100 
revolutions. The tablets weighed after dusting [10].
The friability (F %) is calculated by the formula,
F%=(1−W0/W)×100.
Drug content
The average weight of 20 tablets calculated. 10 mg of tablet powder 
mixed with 100 ml of phosphate buffer (pH 7.2) for complete dissolution. 
Contents filtered and filtrate checked for drug concentration at 227 nm 
by UV spectrometer.
In vitro swelling index
The pre-weighed tablet placed in 5 ml of phosphate buffer (pH 7.2) for 
12 h tablet weight at intervals of 1, 2, 4, 8, 10, and 12 h by taking it out 




Wt=Weight of tablet time t,
Wo=Initial weight.
In vitro drug release study
The dissolution of prepared tablet formulations was carried out 
by obeying various conditions. The dissolution medium chosen is 
combination of acidic buffer pH 1.2 (2 H), phosphate buffer pH 6.8 (4 
H), and phosphate buffer (pH 7.2) in 900 ml dissolution medium. The 
drug content estimated at intervals of 1, 2, 3, 4, 6, 8, 10, 12, and 24 h by 
UV spectroscopy at 227 nm [11].
Drug release kinetics
The drug release data fitted into various linear and non-linear models 
and checked for linearity [12].
Table 1: Evaluation tests of rifaximin colon-targeted tablets
F. No. *Weight variation (mg) #Thickness (mm) #Hardness (kg/cm2) #Friability (%) #Drug content (%) Swelling index (%)
RF1 801.65±1.2 6.0±0.12 6.5±0.12 0.53±0.01 96.23±0.63 75±0.76
RF2 798.69±0.8 6.2±0.06 6.4±0.06 0.56±0.02 96.04±0.06 78±0.72
RF3 798.04±0.5 6.0±0.06 6.3±0.06 0.61±0.03 97.56±0.14 79±0.64
RF4 801.05±0.0 6.2±0.12 6.1±0.12 0.71±0.01 97.11±1.01 87±0.81
RF5 801.54±0.4 6.3±0.00 6.2±0.00 0.64±0.02 95.23±0.8 74±1.03
RF6 800.78±0.4 6.3±0.10 6.8±0.06 0.65±0.01 96.45±0.31 75±0.84
RF7 800.65±0.3 6.2±0.10 6.4±0.10 0.57±0.02 95.18±0.49 72±0.72
RF8 799.57±0.2 6.2±0.25 6.2±0.40 0.68±0.01 96.23±0.51 83±0.79
RF9 800.76±0.35 6.1±0.06 6.5±0.06 0.59±0.00 97.13±0.56 83±0.80
RF10 800.49±0.2 6.3±0.20 6.1±0.42 0.78±0.02 96.23±0.24 78±0.46
RF11 801.53±0.4 6.1±0.06 6.3±0.06 0.75±0.01 98.97±0.21 87±0.67
RF12 802.58±0.3 6.1±0.00 6.5±0.06 0.74±0.02 96.45±0.76 89±0.93
RF13 801.34±0.2 6.2±0.26 6.7±0.35 0.73±0.02 98.45±0.48 97±0.53
RF14 798.67±0.3 6.2±0.21 6.5±0.21 0.75±0.03 97.98±0.23 84±1.08
RF15 799.65±0.2 6.3±0.06 6.8±0.23 0.76±0.02 96.45±0.36 91±0.91
RF16 800.65±0.3 6.1±0.25 6.5±0.23 0.76±0.01 95.45±0.69 87±0.63
RF17 801.79±0.4 6.4±0.15 6.7±0.32 0.77±0.01 94.34±0.35 94±0.48
RF18 801.87±0.1 6.4±0.25 6.6±0.35 0.81±0.01 96.56±0.23 96±0.90
RF19 799.67±0.3 6.2±0.12 6.3±0.12 0.80±0.03 97.29±0.34 91±0.75
RF20 799.32±0.2 6.3±0.12 6.4±0.2 0.65±0.03 98.18±0.81 89±0.67
RF21 800.27±0.4 6.2±0.06 6.3±0.06 0.61±0.02 99.48±0.69 98±0.54
RF22 800.27±0.1 6.3±0.12 6.2±0.12 0.52±0.03 97.18±0.07 97±0.67
RF23 800.26±0.13 6.1±0.17 6.7±0.4 0.77±0.05 98.14±0.76 86±0.54
RF24 800.10±0.5 6.2±0.00 6.8±0.23 0.72±0.08 98.16±0.12 94±0.86
RF25 799.12±0.6 6.2±0.17 6.7±0.12 0.66±0.02 97.23±0.00 92±0.70
RF26 800.16±0.8 6.3±0.10 6.5±0.21 0.71±0.89 97.78±0.23 93±0.68
RF27 800.29±0.15 6.4±0.29 6.4±0.45 0.86±0.03 98.10±0.40 95±0.75
*Values are expressed in mean±standard deviation: (n=20), #Values are expressed in mean±standard deviation: (n=3)
Table 2: Release kinetics of optimized formulation of rifaximin colon-targeted tablets (RF21)
Formulation code Zero order First order Higuchi Korsmeyer–Peppas
R2 K R2 K R2 K R2 N
RF21 0.996 4.165 0.939 0.087 0.937 23.24 0.929 0.865
Table 3: Release kinetics of marketed product
Formulation code Zero order First order Higuchi Korsmeyer–Peppas
R2 K R2 K R2 K R2 N
Marketed formulation 0.936 4.196 0.891 0.083 0.926 19.15 0.909 0.747
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Stability study
The stability of drug tested at 40°C±2°C/75% RH±5% RH for 3 months 
using stability chamber. Sample stability checked at 0, 30, 60, and 
90 days period according to ICH guidelines [13].
RESULTS AND DISCUSSION
The preliminary drug authentication was carried out by UV 
spectrophotometry. The pure rifaximin exhibited absorption maxima 
at 227 nm. Standard calibration curves of the drug plotted in acidic 
buffers of pH 1.2, 6.8, and 7.2 to check the stability of drug in respective 
condition. The results show that the graphs are linear over 2–12 µg/ml 
with R²=0.999 indicating stability of the drug.
Initially, 27 formulations of rifaximin (RF1-RF27) were prepared by 
wet granulation using three variables and three levels of polymers 
of different Eudragit L30D, Carbopol 974P, and ethyl cellulose (low, 
middle, and high concentrations) by design of experiment.
Evaluation parameters of rifaximin colon-targeted tablets
The rifaximin colon-targeted tablets were prepared by varying 
proportions of polymers by wet granulation method and further 
evaluated for following evaluation tests. The results are found to be 
within the pharmacopoeia limits (Table 1).
The weight variations of all formulations are in the limit allowed that is 
±5% of total tablet weight. The crushing strength of fabricated tablets 
is between 6.0 and 7.0 kg/cm2. The thickness of all the formulations 
is between the ranges of 6 and 6.4 mm. The friability was found to 
be between 0.52 and 0.8%. The drug content of all formulations is in 
between 95.18 and 99.48%, indicating even distribution of drug in 
all the formulations. The swelling index of the tablet increases with 
increase in time up to 12 h indicating the drug remains in intestinal 
region until the drug is released completely from the delivery system 
and promotes evacuation after its release.
In vitro drug release studies
The release of rifaximin from different formulations is recorded in 
Figs. 1-4. The studies extended up to 24 h. The highest drug release of 
98.75% found in RF21 of within 24 h. Hence, RF21 is chosen for further 
investigations. The drug release of the marketed product is 82.23% up to 
24 h. A comparative in vitro study plot of optimized formulation (RF21) 
and marketed tablet (conventional and sustained) was recorded (Fig. 5).
In vitro drug release kinetics for optimized (RF21) formulation 
and marketed product
Drug release kinetics was evaluated for optimized formula of rifaximin 
colon-targeted tablets (RF21) and marketed formula (Table 2). The 
regression coefficient of 0.996 for zero-order plot, i.e., indicates 
zero-order mechanism for the drug release. Further, n value obtained 
from the Korsmeyer–Peppas plots, i.e., 0.865 indicating non-Fickian 
(anomalous) transport. The marketed conventional formulation also 
followed the zero-order kinetics (Table 3).
Design of experiment
This method is mainly used to explain the effect of each factor on 
other factors, whether this effect is significant or not, if significant 
how it influences the response. In this present work, the effect of ethyl 




















































































































































Fig. 5: Comparative In vitro study plot of rifaximin colon-targeted 
tablets optimized formulation (RF21) and conventional marketed 
tablet
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Fig. 6: Response surface plot showing the influence of amount of polymer on the release profile of rifaximin colon tablets for cumulative 
percentage drug released
Fig. 7: Response surface plot showing the influence of amount of polymer on swelling index of rifaximin
Table 4: Parameters after accelerated stability study of rifaximin colon-targeted tablet formulation (RF21)
Parameters Temperature maintained at 40±2°C; RH maintained at 75±5%RH
Initial After 1 month After 2 months After 3 months
Drug content (%) 99.48±0.69 98.46±0.65 98.33±0.37 98.32±0.22
In vitro drug release (%) 99.48±0.69 99.39±0.53 99.25±0.42 97.22±0.35
Swelling index (%) 98±0.54 98.0±0.46 98.0±0.37 98.0±0.23
Hardness (Kg/cm2) 6.3±0.66 6.3±0.58 6.3±0.45 6.3±0.37
RH: Relative humidity
In Fig. 6, the effect of ethyl cellulose on percentage cumulative drug 
release shows significant effect of ethyl cellulose on percentage 
cumulative drug release. The percentage cumulative drug release of all 
the three formulations is in between 84.38 and 98.21% but when ethyl 
cellulose is in low concentration, the maximum percentage cooldown 
reduction is near 84.38%. This is the effect of factor (ethyl cellulose) on 
response which is a negligible on swelling index as formulations exhibit 
excellent swelling property and there is slightly influence on swelling 
index by ethyl cellulose (Fig. 7). Overlay plot of rifaximin colon-targeted 
tablets is represented in Fig. 8.
Drug-excipient compatibility studies
FTIR studies spectroscopy
The FTIR spectrum of rifaximin and optimized formulation is shown 
in Figs. 9 and 10. The O-H and C=O stretching in rifaximin pure drug 
were observed at 3448 and 1745 cm−1, respectively, which remained 
intact in physical mixture of rifaximin and excipients. C-H stretching of 
pure drug is at 2924 cm−1, whereas it shows the same peak for physical 
mixture also. C-H bending of pure drug and physical mixture is at 790 
cm−1. The FTIR spectrum of rifaximin optimized formulation RF21 
also exhibited characteristic bands (3437 and 1786 cm−1 for O-H and 
C=O stretching and 2924 cm−1 for C-H stretching, and 790 cm−1 for C-H 
bending) consistent with the molecular structure of rifaximin pure 
drug which indicated that no chemical interaction occurred between 
the drug and excipients used in the formulation.
Stability studies
The stability studies of the optimized formulation (RF21) indicated no 
significant effect on drug release, hardness, drug content, and swelling 
study data. Hence, the formulations are stable (Table 4).
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CONCLUSION
The present study is conducted to formulate pH-sensitive matrix 
tablets of rifaximin for targeted action in proximal colon. Twenty-seven 
formulations of rifaximin (RF1-RF27) were prepared using three levels of 
polymers of different Eudragit L30D, Carbopol 974P, and ethyl cellulose 
(low, middle, and high concentrations) by design of experiments 
software. The results of physicochemical parameter test applied on 
all the formulations designated that the weight variations are within 
allowed limit. The drug content measured for formulations indicates 
uniform drug distribution. Swelling index indicates that drug will remain 
in intestinal region until the drug is released completely from the delivery 
system and promotes evacuation after its release. Drug compatibility 
studies carried out by recording the FTIR spectra indicate no chemical 
interaction between the drug and the excipients used. In vitro drug 
Fig. 8: Overlay plot of rifaximin colon-targeted tablets
Fig. 9: Fourier transform infrared spectrum of pure drug rifaximin
Fig. 10: Fourier transform infrared spectrum of optimized formulation of rifaximin colon-targeted tablets
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release of colon-targeted rifaximin tablets studied up to 24 h. The highest 
drug release of 98.75% found in the RF21 at within 24 h. Drug release 
kinetics for optimized formulation RF21 indicates that it follows zero-
order mechanism. The stability studies indicate no major changes in 
swelling index, hardness, drug content, and in vitro drug release.
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